Literature DB >> 11182567

In vitro and in vivo evaluation of new radiolabeled neurotensin(8-13) analogues with high affinity for NT1 receptors.

E García-Garayoa1, L Allemann-Tannahill, P Bläuenstein, M Willmann, N Carrel-Rémy, D Tourwé, K Iterbeke, P Conrath, P A Schubiger.   

Abstract

The potential utility of neurotensin (NT) in cancer diagnosis and therapy is limited by its rapid degradation. New stabilized analogues were synthesized, labeled with [99mTc] and screened in vitro and in vivo. High affinity and rapid internalization were obtained in binding assays. Despite their longer human plasma half-lives, a rapid degradation was observed with low concentrations as used in biodistribution tests. The tumor uptake rates were rather low but tumor/blood ratios increased according to the stability raise.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11182567     DOI: 10.1016/s0969-8051(00)00190-6

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  14 in total

1.  Modifications at Arg and Ile Give Neurotensin(8-13) Derivatives with High Stability and Retained NTS1 Receptor Affinity.

Authors:  Lisa Schindler; Günther Bernhardt; Max Keller
Journal:  ACS Med Chem Lett       Date:  2019-05-10       Impact factor: 4.345

2.  Enhanced tumor retention of NTSR1-targeted agents by employing a hydrophilic cysteine cathepsin inhibitor.

Authors:  Wei Fan; Wenting Zhang; Sameer Alshehri; Trey R Neeley; Jered C Garrison
Journal:  Eur J Med Chem       Date:  2019-05-25       Impact factor: 6.514

3.  Examination of the impact molecular charge has on NTSR1-targeted agents incorporated with cysteine protease inhibitors.

Authors:  Wei Fan; Wenting Zhang; Sameer Alshehri; Jered C Garrison
Journal:  Eur J Med Chem       Date:  2022-03-08       Impact factor: 6.514

4.  Preclinical PET Imaging of NTSR-1-Positive Tumors with 64Cu- and 68Ga-DOTA-Neurotensin Analogs and Therapy with an 225Ac-DOTA-Neurotensin Analog.

Authors:  Daneng Li; Megan Minnix; Rebecca Allen; James Bading; Junie Chea; Patty Wong; Nicole Bowles; Erasmus Poku; John E Shively
Journal:  Cancer Biother Radiopharm       Date:  2020-08-19       Impact factor: 3.632

5.  Glycosylated neurotensin analogues exhibit sub-picomolar anticonvulsant potency in a pharmacoresistant model of epilepsy.

Authors:  Hee-Kyoung Lee; Liuyin Zhang; Misty D Smith; H Steve White; Grzegorz Bulaj
Journal:  ChemMedChem       Date:  2009-03       Impact factor: 3.466

6.  Investigation of the Biological Impact of Charge Distribution on a NTR1-Targeted Peptide.

Authors:  Yinnong Jia; Wenting Zhang; Wei Fan; Susan Brusnahan; Jered Garrison
Journal:  Bioconjug Chem       Date:  2016-10-21       Impact factor: 4.774

7.  A stable neurotensin-based radiopharmaceutical for targeted imaging and therapy of neurotensin receptor-positive tumours.

Authors:  Elisa García-Garayoa; Peter Bläuenstein; Alain Blanc; Veronique Maes; Dirk Tourwé; P August Schubiger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08-09       Impact factor: 9.236

8.  [99mTc]Demotensin 5 and 6 in the NTS1-R-targeted imaging of tumours: synthesis and preclinical results.

Authors:  Theodosia Maina; Anastasia Nikolopoulou; Eleni Stathopoulou; Athanassios S Galanis; Paul Cordopatis; Berthold A Nock
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-06-27       Impact factor: 9.236

9.  Stabilised 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer.

Authors:  M de Visser; P J J M Janssen; A Srinivasan; J C Reubi; B Waser; J L Erion; M A Schmidt; E P Krenning; M de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-24       Impact factor: 9.236

10.  Synthesis, gallium labelling and characterization of P04087, a functionalized phosphatidylserine-binding peptide.

Authors:  Rana Ben Azzouna; Alexandre Guez; Khadija Benali; Faisal Al-Shoukr; Walter Gonzalez; Philippe Karoyan; François Rouzet; Dominique Le Guludec
Journal:  EJNMMI Radiopharm Chem       Date:  2017-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.